孤立性再次主动脉瓣置换与瓣中瓣经导管主动脉瓣置换的对比研究
单中心回顾性研究比较既往SAVR后行孤立性redo-SAVR(n=86)与VIV-TAVR(n=187)的早中期结局。VIV-TAVR组STS预测死亡风险更高、年龄更大,但两组早期死亡率相似;redo-SAVR组卒中率更高,VIV-TAVR组术后至少轻度主动脉瓣反流更常见。
要点
- 既往SAVR后,redo-SAVR与VIV-TAVR早期死亡率相似。
- redo-SAVR组卒中率高于VIV-TAVR组。
- VIV-TAVR组术后至少轻度主动脉瓣反流更常见。
核心结论
- 既往SAVR后,redo-SAVR与VIV-TAVR均可获得可接受的观察期结果。
- 尽管VIV-TAVR治疗的是高危人群,两种术式的手术结局相似。
- redo-SAVR患者瓣膜血流动力学优于VIV-TAVR患者。
研究设计与样本
- 单中心回顾性研究,纳入2012至2019年初次使用VIV-TAVR的273例既往SAVR患者。
- 其中VIV-TAVR组187例,redo-SAVR组86例。
- 结局分析包括单变量分析和Kaplan-Meier生存分析。
主要发现
- VIV-TAVR组STS预测死亡风险为6.3%(IQR 3.6%-10.5%),高于redo-SAVR组的4.2%(IQR 2.4%-6.9%),P < .01。
- VIV-TAVR组年龄为76岁(IQR 67.5-82.5岁),大于redo-SAVR组的64岁(IQR 54-72岁),P < .01。
- redo-SAVR与VIV-TAVR早期死亡率相似(1.2% vs 1.6%,P = .92)。
- redo-SAVR组卒中率高于VIV-TAVR组(7.0% vs 1.1%,P = .02)。
- 术后平均瓣膜压差VIV-TAVR组为14 mm Hg(IQR 9-21 mm Hg),redo-SAVR组为12 mm Hg(IQR 8-20 mm Hg),P = .08。
临床怎么用
- 对于既往SAVR后需再次主动脉瓣置换的患者,redo-SAVR与VIV-TAVR均可作为治疗选择。
- 选择术式时应综合评估患者手术风险、年龄及瓣膜血流动力学预期。
局限性
- 单中心回顾性研究,样本量有限。
- VIV-TAVR组与redo-SAVR组基线风险与年龄存在显著差异,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical outcomes of redo surgical aortic valve replacement (redo-SAVR) compared with valve-in-valve transcatheter aortic valve replacement (VIV-TAVR) are poorly understood. This study compared short- and midterm outcomes of patients undergoing isolated redo-SAVR vs VIV-TAVR after previous SAVR. METHODS: A single-institutional review of the initial use of VIV-TAVR from 2012 to 2019 identified 273 patients undergoing VIV-TAVR (n = 187) or redo-SAVR (n = 86) after prior SAVR. Outcomes analysis included a univariate analysis and Kaplan-Meier survival analysis. RESULTS: The Society of Thoracic Surgeons predicted risk of mortality was higher for VIV-TAVR (6.3%; interquartile range [IQR], 3.6%-10.5%) vs redo-SAVR (4.2%; IQR, 2.4%-6.9%; P < .01). VIV-TAVR patients (76 years; IQR, 67.5-82.5 years) were older than redo-SAVR patients (64 years; IQR, 54-72; P < .01). Redo-SAVR and VIV-TAVR had similar early mortality (1.2% vs 1.6%, P = .92). Two redo-SAVR (2.3%) and 3 VIV-TAVR patients (1.6%) died 4.8 ± 0.5 years and 4.8 ± 1.5 months after discharge, respectively. Redo-SAVR had an increased stroke rate (7.0% vs 1.1%, P = .02). Postoperative mean valve gradients were similar between VIV-TAVR (14 mm Hg; IQR, 9-21 mm Hg) and redo-SAVR patients (12 mm Hg; IQR, 8-20 mm Hg; P = .08). Postprocedure transesophageal echocardiography showed at least mild aortic insufficiency for 24 VIV-TAVR patients (16%) and 2 redo-SAVR patients (2.9%) (P = .01). The cumulative incidence of aortic valve reintervention was 5.2% for the redo-SAVR patients and 28.5% for the VIV-TAVR patients (P = .07). CONCLUSIONS: After previous SAVR, redo-SAVR and VIV-TAVR can both be performed with acceptable operative results. Despite treating a high-risk patient population, we found redo-SAVR and VIV-TAVR both carry similar operative outcomes. Improved valve hemodynamics were observed in redo-SAVR patients compared with VIV-TAVR patients.
引用
- Patel PM, Chiou E, Cao Y, et al. Isolated Redo Aortic Valve Replacement Versus Valve-in-Valve Transcatheter Valve Replacement. Ann Thorac Surg. 2020. PMID: 33129775. doi:10.1016/j.athoracsur.2020.08.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。